Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man - Wikidata - awgldk - TriplyDB

Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man

Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man

http://www.wikidata.org/entity/Q36562488

about

SIRT1: A Novel Target for the Treatment of Muscular Dystrophies Redox regulation of SIRT1 in inflammation and cellular senescence Sirtuins and nonalcoholic fatty liver disease Sirtuin deacylases: a molecular link between metabolism and immunity Slowing ageing by design: the rise of NAD(+) and sirtuin-activating compounds A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis Editors' pick 2013.Small-molecule allosteric activators of sirtuins.Targeting sirtuins for the treatment of diabetes A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes.SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass Dysfunction of endothelial progenitor cells from smokers and chronic obstructive pulmonary disease patients due to increased DNA damage and senescence.A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers.Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours Sirtuin 1 activator SRT2104 protects Huntington's disease mice.Neurological and histological consequences induced by in vivo cerebral oxidative stress: evidence for beneficial effects of SRT1720, a sirtuin 1 activator, and sirtuin 1-mediated neuroprotective effects of poly(ADP-ribose) polymerase inhibition Potential compounds for the treatment of mitochondrial disease.SIRT1 Activity Is Linked to Its Brain Region-Specific Phosphorylation and Is Impaired in Huntington's Disease Mice.Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers.Sirtuin activation as a therapeutic approach against inborn errors of metabolism.Pharmacological approaches to restore mitochondrial function.Small molecule SIRT1 activators for the treatment of aging and age-related diseases.Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11.Approaches to intravenous clinical pharmacokinetics: Recent developments with isotopic microtracers.SIRT1 activates the expression of fetal hemoglobin genes SIRT1 and SIRT6 Signaling Pathways in Cardiovascular Disease Protection.Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs.Epigenetic drug discovery: breaking through the immune barrier.Cardiometabolic effects of a novel SIRT1 activator, SRT2104, in people with type 2 diabetes mellitus.New findings rejuvenate age-old drug development field.Mass spectrometric studies on the in vitro generated metabolites of SIRT1 activating drugs for doping control purposes.Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors.Application of (14)C-accelerator MS in pharmaceutical development.

P2860

Q26748736-BB7208D1-C28B-4034-BACD-CA75E1B8ECF2 Q27023972-66C72E74-2CFC-4F02-9F45-C395F716E84B Q28079953-84F54092-6B2A-4C38-A639-57A7733714DB Q28283588-F36F6013-6D42-444B-974B-BCF24821F0D5 Q28314993-E806653B-F22A-4AFE-B517-0DA459EEFADB Q28550785-6A008B20-9967-4D3F-B1FA-7B4B1C1FA375 Q33582058-E964DF60-A612-4C53-98CC-494FAE23BB0C Q33601236-AE224F5B-25B3-49C5-BDDD-5A3840E1F3EA Q33946771-8E2826C9-D437-4AF3-93B9-58850366BF90 Q34209516-EDFA203E-8A7E-4D3C-B9AE-662AC5FC9D82 Q34232012-3C20DABE-1949-45B7-A174-E2C18A4E128B Q34360591-B897DD06-8F1D-4C49-A218-ED645B8745CF Q34531843-9AD02315-17AA-430A-8D55-EB3C10C6A39D Q34538482-419443C3-625D-492B-A6D4-1FA8D599B449 Q34571039-CC37C348-36E1-4182-8A46-56AABC3B27F4 Q34824858-5527A3D7-D90F-421D-BF6A-2ACA1D3D4B2C Q35105920-08CE3D4F-B124-491A-81BE-1551CAF83630 Q35847813-985C448E-9141-45BA-81A4-A7335BB784AD Q35905545-2B5F3FBB-D4BD-4CD8-AA3C-41799FAF671C Q36947788-66DBB3B4-45B9-496F-80B2-9A3898064C56 Q36956287-F71B5094-F927-4C8B-A0CB-5B30E539C776 Q36974218-F4AB948F-6576-4A1E-B4A4-D311EC3EB12F Q37037635-AB7FA256-CE6D-4C61-8691-80E127168108 Q37497833-B1E7EAEB-1CAD-4132-980E-FD2D6E8E0866 Q37673310-91D422BC-2CFE-4C66-9E1D-B9EA483B57A5 Q38233723-6F68E064-64F7-49F2-BC03-0FF3B6C8FF60 Q38527478-9BAA543C-6E2D-4A65-8245-43560F63E7DD Q38641406-70F57609-B85F-4967-BF94-1CA15F40E9E5 Q38665115-AC9386F8-2806-4B92-B2D1-1422A5ED9937 Q38912441-1E8B2E40-6322-45C1-907A-463CE1E9C60D Q38986705-8DDF6450-109E-48A5-8699-0F1070A06286 Q41582070-1AEFE7C7-4AD1-4AA2-8DE9-2B3B01531A71 Q45900482-BC067DCF-A772-4E05-AF6E-B706D931E60B Q46569842-4FEF9EE5-F4F9-4741-B06F-0DAAE4815952 Q48022375-60400632-56FB-4B9F-893A-488EEBEE85F7 Q53226670-83E5A16F-B5D9-4FDA-9602-3784DC083652

P2860

Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man

http://www.wikidata.org/entity/Q36562488

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Pharmacokinetics and tolerabil ...... ted oral administration in man

@ast

Pharmacokinetics and tolerabil ...... ted oral administration in man

@en

type

label

Pharmacokinetics and tolerabil ...... ted oral administration in man

@ast

Pharmacokinetics and tolerabil ...... ted oral administration in man

@en

prefLabel

Pharmacokinetics and tolerabil ...... ted oral administration in man

@ast

Pharmacokinetics and tolerabil ...... ted oral administration in man

@en

P1433

Q36562488-8E489BE1-6165-46B6-96C6-87B6FE1A95AC

P1476

Q36562488-F36B6F43-9129-48C0-B50E-753E81B45711

P2093

Q36562488-0AB5083B-2B81-4248-B34D-58FCD5286B61

Q36562488-1B3A1213-66BA-49BB-83AA-279EE83E98E8

Q36562488-1E896A4F-7310-4A6A-A888-8AC560274AB0

Q36562488-3772F593-4CE1-414C-8903-A7C870B24884

Q36562488-7FAF55BE-0C74-4AC4-B6D2-D00C7EFFE3F9

Q36562488-8B7BCB33-8178-4C4B-B0B2-EA58381A9658

Q36562488-B4FD3AB8-92A5-40B2-B717-CE54B6E03FD6

Q36562488-BB29F875-4278-4280-8694-EC966BDAE217

Q36562488-F489DC6A-3129-458A-8866-9596763C1520

P2860

Q36562488-00C54418-371F-4DDC-A661-3B2C0B642C73

Q36562488-078C870F-BCF8-4722-91D5-D160D4323CB1

Q36562488-096E7B6F-A3C2-4567-BF8E-3BF4A4DDE58A

Q36562488-0B7B8EF5-D335-481B-B753-11A960175746

Q36562488-13973B6F-C4DD-4E47-BDB6-7C87903B98A5

Q36562488-182D04FF-0C58-4DCC-9B87-4B2ED91A1255

Q36562488-1AEBE18F-2172-4C9B-A3AF-FD81FA851D1A

Q36562488-271729F4-AAC2-4351-9ED7-053ECB920434

Q36562488-2BB74FFD-1081-464C-804D-DEF6A5AE5696

Q36562488-2BC18F51-F82C-478B-A1EE-19233415B7A0

P304

Q36562488-B5EC216E-1883-4E3E-B370-C736B6E838E7

P31

Q36562488-0886D1F9-340B-454D-8242-83928F424C56

P356

Q36562488-BBED7D64-647A-4055-A24D-7363896C5F73

P407

Q36562488-8587BC99-BC6D-42B5-90AD-01250CD3A781

P433

Q36562488-0B8CF0A4-5CEB-4CE0-8C8E-853CB3F7332C

P478

Q36562488-55DBE283-A658-43AF-9A2F-9B33F1D04BF6

P577

Q36562488-CFDBECA9-5DB4-46C1-A399-9BE2F9CDA320

P5875

Q36562488-5A8647E5-05DF-4C01-8934-63F062C1E209

P698

Q36562488-5DA39D5E-2EB3-4C06-AED8-8AEED22B1592

P932

Q36562488-2B8966C0-F574-455F-9B2C-1978AA574556

P356

J.1365-2125.2012.04340.X

P1433

British Journal of Clinical Pharmacology

P1476

Pharmacokinetics and tolerabil ...... ted oral administration in man

@en

P2093

Christoph Westphal

http://www.w3.org/2001/XMLSchema#string

Claire Beaumont

http://www.w3.org/2001/XMLSchema#string

Eric Jacobson

http://www.w3.org/2001/XMLSchema#string

Ethan Hoffmann

http://www.w3.org/2001/XMLSchema#string

Jeff Wald

http://www.w3.org/2001/XMLSchema#string

John Roberts

http://www.w3.org/2001/XMLSchema#string

Jon Haddad

http://www.w3.org/2001/XMLSchema#string

Peter Elliott

http://www.w3.org/2001/XMLSchema#string

Siva Lavu

http://www.w3.org/2001/XMLSchema#string

P2860

hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase

Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase.

Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2

Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma

Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase

Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase

Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins

Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases

Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases

SRT1720 improves survival and healthspan of obese mice

P304

186-196

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.2012.04340.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225055515

http://www.w3.org/2001/XMLSchema#string

P698

22616762

http://www.w3.org/2001/XMLSchema#string

P932

3555058

http://www.w3.org/2001/XMLSchema#string